Federal Register #2026-07769

Licensing Opportunity: Monoclonal Antibody Technologies Against West Nile Virus from NIAID

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS), is offering licensing opportunities for government-owned inventions targeting West Nile Virus (WNV): - Government Buyer: - Department of Health and Human Services (HHS) - National Institutes of Health (NIH) - National Institute of Allergy and Infectious Diseases (NIAID) - OEMs and Key Collaborators: - NIAID (as the developer and owner of the technology) - Sheba Medical Center (collaborator) - Israeli Ministry of Health (collaborator) - Products/Technologies Available for Licensing: - Fully human monoclonal antibodies that neutralize West Nile Virus (WNV) - Includes seven specific antibody sequences: AIS196, AIS204, AIS259, AIS260, AIS261, AIS262, AIS265 - Compositions, nucleic acids, vectors, and host cells for antibody production - Engineered antibody versions for extended activity and immune modulation - Methods for prevention, treatment, detection, and surveillance of WNV infection - Intellectual property references: HHS Reference No. E20020240 and E02120260 - Unique/Notable Requirements: - This is a technology licensing and collaborative research opportunity, not a procurement of physical products - No specific quantities or part numbers for products; focus is on intellectual property and commercialization - Foreign patent applications may be available to extend market coverage - Points of Contact and Locations: - Technology Transfer and Intellectual Property Office, NIAID, 5601 Fishers Lane, Rockville, MD 20852 - Sheba Medical Center (collaborator location)

Description

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), announces the availability for licensing of government-owned inventions. These inventions include neutralizing monoclonal antibodies against West Nile Virus (WNV) that have potential applications in prevention, treatment, diagnostics, and research. The notice aims to promote commercialization of federally funded research and development, with foreign patent applications filed on selected inventions to extend market coverage. Interested parties may contact the Technology Transfer and Intellectual Property Office for licensing and collaboration opportunities.

View original listing